Moneycontrol PRO
windlas biotech
Jump to
22 Results Found
  • Windlas Biotech Standalone June 2021 Net Sales at Rs 110.96 crore, up 8.49% Y-o-Y Sep 09, 2021 08:44 AM IST

    Windlas Biotech Standalone June 2021 Net Sales at Rs 110.96 crore, up 8.49% Y-o-Y

  • Bulk deals | Morgan Stanley offloads 2.5 lakh shares in Exxaro Tiles; promoter sells 20 lakh shares in KNR Constructions Aug 16, 2021 09:22 PM IST

    Bulk deals | Morgan Stanley offloads 2.5 lakh shares in Exxaro Tiles; promoter sells 20 lakh shares in KNR Constructions

    Welspun Multiventures LLP bought 5,21,565 equity shares in Spencer's Retail at Rs 104.5 per share.

  • Windlas Biotech shares settle with 11.6% loss to issue price in debut trade Aug 16, 2021 05:51 PM IST

    Windlas Biotech shares settle with 11.6% loss to issue price in debut trade

    Cumulatively, Windlas Biotech traded with volume of 44.3 lakh equity shares on the BSE and NSE.

  • Windlas Biotech listing disappoints, Exxaro Tiles jumps 10%: What should investors do now? Aug 16, 2021 04:13 PM IST

    Windlas Biotech listing disappoints, Exxaro Tiles jumps 10%: What should investors do now?

    Most experts Moneycontrol spoke to advise holding Windlas Biotech shares for the long term while short-term investors can book profits. As for Exxaro, the advise booking profits.

  • Krsnaa Diagnostics, Windlas Biotech, Exxaro Tiles to debut on August 16: What could be listing premium? Aug 15, 2021 05:18 PM IST

    Krsnaa Diagnostics, Windlas Biotech, Exxaro Tiles to debut on August 16: What could be listing premium?

    Considering healthy response from all the category investors, Prashanth Tapse of Mehta Equities believe Windlas Biotech would list around Rs 540-550 levels, which translates to 18-20 percent premium.

  • Windlas Biotech, Exxaro Tiles listing: Grey market premium ahead of debut Aug 14, 2021 05:34 PM IST

    Windlas Biotech, Exxaro Tiles listing: Grey market premium ahead of debut

    Windlas and Exxaro opened their public issues on August 4 and will close on August 6 after being subscribed 22.47 times and 22.68 times respectively.

  • Windlas Biotech IPO share allotment likely to be finalised on August 11 Aug 11, 2021 05:06 PM IST

    Windlas Biotech IPO share allotment likely to be finalised on August 11

    Windlas Biotech shares were available for trading at a premium of Rs 65 or 14.1 percent in the grey market, compared to expected final issue price of Rs 460, the IPO Watch data showed. The trading price comes to Rs 525 per share.

  • Windlas Biotech IPO oversubscribed by 22.47 times, QIB portion booked 24.4 times on final day Aug 06, 2021 12:01 PM IST

    Windlas Biotech IPO oversubscribed by 22.47 times, QIB portion booked 24.4 times on final day

    Windlas Biotech IPO: Investors in the grey market traded shares of Windlas Biotech at a premium of Rs 90-110, the IPO Watch and IPO Central data showed.

  • Windlas Biotech IPO closes today: Why brokers are pressing 'subscribe' button Aug 06, 2021 09:54 AM IST

    Windlas Biotech IPO closes today: Why brokers are pressing 'subscribe' button

    Windlas Biotech IPO: Its innovative portfolio of complex generic products, robust R&D capabilities, efficient and quality-compliant manufacturing facilities are among the main factors. In fact, one brokerage house said that though the issue seems to be fully priced, factoring in the growth drivers of the CDMO sector and opportunities available for the company, investors can subscribe to the issue.

  • Subscribe to Windlas Biotech: Prabhudas Lilladher Aug 05, 2021 02:56 PM IST

    Subscribe to Windlas Biotech: Prabhudas Lilladher

    Prabhudas Lilladher has come out with its report on Windlas Biotech. The research firm has recommended to ''Subscribe'' the ipo in its research report as on August 05, 2021.

  • Windlas Biotech IPO: Retails investors lead charge, issue subscribed 7.06 times on Day 2 Aug 05, 2021 12:18 PM IST

    Windlas Biotech IPO: Retails investors lead charge, issue subscribed 7.06 times on Day 2

    Windlas Biotech shares were trading at a premium of Rs 110-130 in the grey market, translating into a 23.9-28.3 percent premium over the issue price of Rs 460, the IPO Watch and IPO Central data shows

  • Subscribe to Windlas Biotech: Hem Securities Aug 05, 2021 09:01 AM IST

    Subscribe to Windlas Biotech: Hem Securities

    Hem Securities has come out with its report on Windlas Biotech. The research firm has recommended to ''Subscribe'' the ipo in its research report as on August 03, 2021.

  • Windlas Biotech IPO subscribed 3.17 times on day 1, retail portion booked 6.15 times Aug 04, 2021 12:28 PM IST

    Windlas Biotech IPO subscribed 3.17 times on day 1, retail portion booked 6.15 times

    In the grey market, Windlas shares traded at a premium of Rs 100-130, the IPO Watch and IPO Central data showed. The trading price comes to Rs 560-590 per share, up 21.7-28.3 percent over the issue price of Rs 460.

  • Subscribe to Windlas Biotech: Choice Equity Broking Aug 03, 2021 11:50 PM IST

    Subscribe to Windlas Biotech: Choice Equity Broking

    Choice Equity Broking has come out with its report on Windlas Biotech. The research firm has recommended to ''Subscribe'' the ipo in its research report as on July 30, 2021.

  • Subscribe to Windlas Biotech: KR Choksey Aug 03, 2021 11:49 PM IST

    Subscribe to Windlas Biotech: KR Choksey

    KR Choksey has come out with its report on Windlas Biotech. The research firm has recommended to ''Subscribe'' the ipo in its research report as on August 03, 2021.

  • Windlas Biotech mobilises Rs 120.46 crore from 22 anchor investors ahead of IPO Aug 03, 2021 09:22 PM IST

    Windlas Biotech mobilises Rs 120.46 crore from 22 anchor investors ahead of IPO

    Marquee investors who participated in the anchor book were Macquarie, Optimix Wholesale Global Emerging Markets, Invesco Trustee, Kuber India Fund, and Elara India Opportunities Fund.

  • IPO-bound Windlas Biotech plans to build CDMO injectable biz, trade generics Aug 03, 2021 04:59 PM IST

    IPO-bound Windlas Biotech plans to build CDMO injectable biz, trade generics

    Hitech Windlas, Managing Director of Windlas Biotech in an interview to Moneycontrol said the company plans to use about 50 crore of the proposed IPO proceeds as capex to build new injectable unit at Dehradun Plant-II, about 20 crore will be for debt repayment, the remaining for working capital and general corporate practices.

  • Windlas Biotech IPO: 10 key things to know before the issue opens Aug 03, 2021 02:56 PM IST

    Windlas Biotech IPO: 10 key things to know before the issue opens

    Windlas Biotech is amongst the top five players in the domestic pharmaceutical formulations CDMOs in terms of revenue, with focus on the chronic therapeutic category.

  • Four IPOs open for subscription today, to raise over Rs 3,600 crore: Which one should you bet on? Aug 03, 2021 10:14 AM IST

    Four IPOs open for subscription today, to raise over Rs 3,600 crore: Which one should you bet on?

    Primary market investors will be spoilt for choice this week. Experts are of the view that two of them will be good for both listing gains and long-term wealth-building.

  • Windlas Biotech IPO: Price band fixed at Rs 448-460, to raise Rs 401.53 crore Jul 29, 2021 08:10 AM IST

    Windlas Biotech IPO: Price band fixed at Rs 448-460, to raise Rs 401.53 crore

    Windlas Biotech IPO: Promoter Vimla Windlass will sell 11.36 lakh equity shares, and investor Tano India Private Equity Fund II will offload its entire stake of 40,06,067 equity shares (or 22 percent of pre-offer paid up equity) via offer for sale.

  • Windlas Biotech IPO to open on August 4, Tano India PE Fund to reduce entire stake Jul 28, 2021 06:55 PM IST

    Windlas Biotech IPO to open on August 4, Tano India PE Fund to reduce entire stake

    The company will separately announce price band and lot size for its IPO in coming few days. The issue will close on August 6.

  • Windlas Biotech files DRHP with Sebi, to raise funds via IPO May 16, 2021 04:39 PM IST

    Windlas Biotech files DRHP with Sebi, to raise funds via IPO

    For the nine months ended December 31, 2020, the company had a profit of Rs 9.67 crore.

Sections
ISO 27001 - BSI Assurance Mark